The influence of adiponectin gene polymorphism on the rosightazone response in patients with type 2 diabetes

OBJECTIVE - The aim Of this study was to examine the effects of rosightazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS - A total of 166 patients with type 2 diabetes were treated with rosiolitazone (4 mg/day) for 1.2 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined. RESULTS - Regarding SNP45. there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA(1c) value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase In the serum adiponectin concentration For the GG genotype than for the Other genotypes (P = 0.003). Regarding SNP276. there was less reduction In the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA(1c) levels were smaller for the GG homozygote haplotype than for the other halotypes PCs (P = 0.001 and 0.001. respectively). The increase in the plasma adiponectin concentration for the GG homozygote haplotype was smaller than that of the other haplolypes (P = 0.003). CONCLUSIONS - These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.